Pain/Inflammation Featured Articles
-
Emerging CROs – One Step Forward And Two Steps Back
4/24/2012
In discussions with executives in pharma and bio, emerging markets are a hot topic. No longer are emerging markets places where companies can expect to be successful simply by attempting to market products developed in other countries and retrofittedto function in the developing country. By Rob Wright, Chief Editor, Life Science Leader magazine
-
Bringing A Billion-Dollar Drug To Market
1/4/2012
A report by Deloitte on the world’s 12 largest drugmakers shows that the average cost of bringing a product to market rose by more than 25% to greater than $1B in 2011, from $830M in 2010. By Cindy Dubin
-
Insights And A Peek Into The Future For PRO & ePRO
12/12/2011
PHT Corporation’s U.S. PRO & ePRO Congress, held in Boston Nov. 9-10, shared electronic patient reported outcome (ePRO) adoption growth numbers, discussions of new regulatory guidance, actionable information that can ease site and study subject burden from ePRO, PRO and ePRO in post-approval, and lingering reasons for sponsor reluctance to adopt ePRO. By Sara Gambrill
-
Streamlining Site And Patient Management
11/2/2011
An emerging paradigm in biopharmaceutical drug development focuses on making patients the center of clinical trials. By Jim Murphy and Sam Whitaker, Life Science Leader magazine
-
Neuro Innovators: Reformulating Pain Therapy Products Into Potential Blockbusters
In recent years, several older opioid drugs have been reformulated and reintroduced to the market with great commercial success due to their ability to address significant unmet medical needs in the marketplace.